PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315I

Turkina, A.G.; Vinogradova, O.; Lomaia, E.; Shatokhina, E.; Shukhov, O.A.; Zaritskey, A.; Chelysheva, E.Y.; Shikhbabaeva, D.; Nemchenko, I.; Petrova, A.; Bykova, A.; Shuvaev, V.; Siordia, N.; Cortes, J.E.; Gale, R.P.; Baccarani, M.; Ottmann, O.; Mikhailov, I.; Novikov, F.; Shulgina, V.; Chilov, G.

Авторы: Turkina Anna G., Vinogradova Olga, Lomaia Elza, Shatokhina Evgeniya, Shukhov Oleg A., Zaritskey Andrey, Chelysheva Ekaterina Yu, Shikhbabaeva Dzhariyat, Nemchenko Irina, Petrova Anna, Bykova Anastasiya, Shuvaev Vasily, Siordia Nadia, Cortes Jorge E., Gale Robert Peter, Baccarani Michele, Ottmann Oliver, Mikhailov Ilya, Novikov Fedor, Shulgina Veronika, Chilov Ghermes
Журнал: Blood
Том: 138
Номер: Supplement 1
Год издания: 2021
Издательство: American Society of Hematology
Местоположение издательства: United States
Первая страница: 1482
Последняя страница: 1482
DOI: 10.1182/blood-2021-150120
Аннотация: Background: Not everyone with CML responds optimally to TKI-therapy, especially those with BCR::ABL1T315I. PF-114 is a 4 th-generation oral tyrosine kinase-inhibitor (TKI) active against wild-type and mutated BCR::ABL1 isoforms including BCR::ABL1T315I. We present final results of a phase-1 study (NCT02885766).Methods: 3+3 dose-escalation study to determine maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). Secondary objectives included safety and efficacy based on haematological, cytogenetic and molecular response criteria. Adverse events (AEs) were graded using NCI-CTCAE v4.03.Results: 51 subjects (5 with accelerated phase CML, 46 - with chronic CML), 23 males, were studied. Daily doses were 50-600 mg/d given once daily continuously. Median age was 50 y (range, 29-82 y). Median CML duration pre-study was 10 y (range, 0.3-23 y). 16 subjects had BCR::ABL1T315I. 25 subjects received ≥ 3 prior TKIs. Median follow-up was ≥ 31 mo and median exposure, 6 mo (range, 0.4-52). Therapy was ongoing in 7 subjects at study termination. Others discontinued because of progression (n = 20), AEs (n = 2), consent withdrawal (n = 5), entry into another study (n = 3) or other reasons (n = 14). The MTD was 600 mg with the grade-3 psoriasis-like skin AE as the DLT. There were no vascular occlusive events or deviations of ankle-brachial index. Complete haematologic response (CHR) was achieved in 14 of 30 subjects, major cytogenetic response (MCyR) in 15 of 44 subjects, complete cytogenetic response (CCyR) in 11 of 50 subjects and major molecular response (MMR) in 8 of 51 subjects. Median duration of CHR was 12 mo and has not been reached for MCyR, CCyR and MMR. The best safety/efficacy dose was 300 mg/d with 6 of 9 subjects achieving a MCyR, 5, a CCyR and 4, MMR. 5 of 16 subjects with BCR::ABL1T315I responded, including 4 achieving a MCyR, 2, a CCyR and 1, a MMR. 2 of 6 subjects failing ponatinib achieved a CHR.Conclusion: PF-114 was safe and effective in subjects failing ≥ 2 TKIs and those with BCR::ABL1T315I including those failing ponatinib. The PF-114 dose for further study is 300 mg/d.
Добавил в систему: Михайлов Илья Александрович

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ИНХС РАН

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315Iстатья Тезисы

Прикрепленные файлы